IL17A and type 1 diabetes mellitus: Wip1−/−MSCs also could home to the pancreas in T1DM mice, leading to an increase of IFN-α, IL-17a, and TNF-α, and decrease of IL-4 and IL-10 in the pancreas, which exacerbated the inflammatory response and deterioration of clinical symptoms in T1DM mice.